Marksans Pharma Limited has announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3 and 9M FY26). For the third quarter of FY26, the company reported a consolidated operating revenue of ₹754.4 crore, marking a year-on-year increase of 10.6%. This growth was primarily driven by strong traction in the US market, supported by seasonal demand and new product launches. EBITDA for the quarter stood at ₹160.7 crore, a 23.2% rise year-on-year, with EBITDA margins expanding to 21.3% from 19.1% in Q3 FY25. Profit After Tax (PAT) for the quarter was ₹113.7 crore, an increase of 8.2% compared to the same period last year. The company highlighted sequential improvements in gross margins due to softening raw material costs, favorable currency movements, and an improving product mix. For the nine-month period ended December 31, 2025 (9M FY26), operating revenue grew by 9.4% year-on-year to ₹2,094.8 crore. EBITDA for 9M FY26 was ₹405.4 crore, broadly flat year-on-year, with margins at 19.4%. PAT for the nine months declined by 7.1% to ₹271.0 crore, attributed to factors including weaker EBITDA in the early part of FY26, higher lease-related finance costs, and lower other income. The management commentary noted a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6% YoY. Margins expanded sequentially, driven by raw material costs, currency movements, and product mix. The company also announced strengthening its global footprint through new subsidiaries in Europe and Canada. Key financial highlights for Q3 FY26 include a Gross Profit of ₹438.2 crore and a Net Profit Margin of 14.7%. The company incurred R&D spends of ₹62.0 crore in 9MFY26, representing 3.0% of consolidated revenue. Cash generated from operations was ₹263.2 crore during 9MFY26, with a cash balance of ₹824.2 crore as of December 31, 2025. The company also received marketing authorizations for several products, including Mefenamic Acid tablets, Loperamide Hydrochloride Tablets, and Cetirizine Dihydrochloride Oral Solution.
